和鉑醫藥－Ｂ (2142.HK)

1.250 +0.060 (+5.04%) 收市：04:08PM HKT

和鉑醫藥－Ｂ

Tower A, 12th Floor
Fenglin International Plaza Phase II 420 Fenglin Road Xuhui District
Shanghai 200032
China
86 21 5339 9123
https://www.harbourbiomed.com

版塊: Healthcare
行業: Biotechnology
全職員工: 177

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Jingsong Wang M.D., Ph.D.	Founder, Chairman & CEO	103.85M	無	1965
Mr. Weihao Xu	CFO, Chief Business Officer and Global Head of Business & Corporate Development	無	無	1983
Dr. Yiping Rong Ph.D.	Chief Scientific Officer & Executive Director	無	無	1977
Mr. Bruce Zhang	Head of Legal	無	無	無
Dr. Peter F. Moesta Ph.D.	Member of Scientific Advisory Board & Chief CMC Advisor	無	無	無
Dr. Xiaolu Tao	Chief Development Officer	無	無	1974
Dr. Steve Arkinstall DPhil	Chief Scientific Advisor	無	無	無
Mr. Wing Yat Lui	Company Secretary	無	無	1990

截止 2021年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9378 for the treatment of Asthma; and HBM1020, HBM1007, HBM1022, HBM7022, HBM9027, HBM9033, HBM7004, HBM1047, and HBM9014 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.

公司管治

截至 無 止，和鉑醫藥－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。